Jacques Banchereau

Biography

Jacques Banchereau has a 35-year track record of academic and industrial research leadership in immunology. At the Schering-Plough/DNAX Laboratory for Immunological Research in Lyon, France, Dr. Banchereau made significant contributions towards 1) the discovery and characterization of numerous human cytokines, including IL4, IL-10, IL-13, IL-17 and GM-CSF; 2) human B–cell biology, in particular B-cell growth, differentiation and isotype switching; 3) developing methods for in vitro–generation of human dendritic cells (DCs) and 4) functional characterization of various DC subsets. As Director of the Baylor Institute for Immunology Research (BIIR) in Dallas, Texas, Dr Banchereau facilitated major advances in our understanding of human DC biology and the therapeutic use of DCs in cancer and infectious diseases. Dr Banchereau also helped to identify the role of Type I interferon in Systemic Lupus Erythematosus (SLE) and IL-1 in Systemic Onset Juvenile Idiopathic Arthritis (sJIA), which led to the novel application of IL-1 antagonists as powerful therapeutics for juvenile arthritic disease. Dr. Banchereau also contributed to the development of DC-based vaccines for use in a series of clinical trials for the treatment of metastatic melanoma as well as for HIV infection. As Chief Scientific Officer of the Hoffmann-La Roche (Roche) Nutley, NJ campus, Dr. Banchereau oversaw the Discovery and Development unit (including Phase IIb clinical trials) in the areas of virology and inflammation. Dr. Banchereau is currently Professor, Director of Immunological Sciences and the Deputy Director of JAX Genomic Medicine (JAX-GM) facility in Farmington, CT. Dr. Banchereau is a graduate of University of Angers and University of Paris, France and has published over 450 original research papers.

Research Interest

business